- Home
- DHF vs STXS Comparison
DHF vs STXS Comparison
Compare DHF & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DHF | STXS |
|---|---|---|
| Founded | 1998 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.7M | 210.0M |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | DHF | STXS |
|---|---|---|
| Price | $2.51 | $2.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 451.1K | ★ 471.8K |
| Earning Date | 01-01-0001 | 11-11-2025 |
| Dividend Yield | ★ 7.65% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,075,000.00 |
| Revenue This Year | N/A | $24.48 |
| Revenue Next Year | N/A | $29.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 19.62 |
| 52 Week Low | $2.06 | $1.54 |
| 52 Week High | $2.39 | $3.59 |
Technical Indicators
Market Signals| Indicator | DHF | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 44.30 | 44.44 |
| Support Level | $2.49 | $2.34 |
| Resistance Level | $2.55 | $2.44 |
| Average True Range (ATR) | 0.02 | 0.10 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 33.33 | 55.17 |
Price Performance
Historical ComparisonAbout DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.
About STXS Stereotaxis Inc.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.